Uses of IL-12 in hematopoiesis

摘要

Methods for enhancing or stimulating hematopoiesis including the step of administering Interleukin-12 (IL-12) to yield hematopoietic recovery in a mammal in need. Preferred methods include the step of administering IL-12 as an adjuvant therapy to alleviate the hematopoietic toxicities associated with one or more treatment regimens used to combat a disease state. Other methods include administering IL-12 to ameliorate various hematopoietic deficiencies. Still other methods are directed to uses of IL-12 for in-vivo proliferation of hematopoietic repopulating cells, hematopoietic progenitor cells and hematopoietic stem cells. Other disclosed methods are directed to uses of IL-12 for bone marrow preservation or recovery.

主权项

1. A method for protecting or restoring hematopoiesis or enhancing peripheral blood cell counts in a mammal having at least one solid tumor, wherein the method comprises:
(a) administering a treatment to the mammal, wherein the treatment targets the solid tumor and has an associated hematopoietic toxicity, and wherein the treatment is selected from the group consisting of radiation therapy and a combination of chemotherapy and radiation therapy; and (b) administering one single therapeutically effective dose of interleukin-12 (IL-12), wherein:
(i) the administration of IL-12 to the mammal reduces the hematopoietic toxicity of the treatment;(ii) the dose of IL-12 is from 1 ng/kg up to 400 ng/kg;(iii) IL-12 is administered without the addition of other cytokines;(iv) IL-12 is administered about 36 hours before the treatment, about 24 hours before the treatment, about 12 hours before the treatment, within 1 hour after the treatment, about 1 hour after the treatment, about 12 hours after the treatment, or about 24 hours after the treatment; and(v) no additional dose(s) of IL-12 is administered near the time of administration of the treatment.